Table 5. Phase II trials with EGFR TKI in first-line NSCLC pts harboring EGFR mutations.

Trial	Study population	Treatment	No. of pts screened	EGFR mut	No. pts treated	RR (%)	mPFS (months)
Inoue	CT-naive	Gefitinib	75	25	16	75	9.7
Asahina	CT-naive	Gefitinib	82	20	16	75	8.9
WJTOG0403	CT naive or up to 2 prior CT	Gefitinib	118	32	28	75	11.5
iTARGET	CT naive	Gefitinib	98	34	31	55	9.2

EGFR, epidermal growth factor receptor; TKIs, tyrosine-kinase inhibitors; NSCLC, non-small cell lung cancer; RR, response rates.